(NASDAQ: ABCL) Abcellera Biologics's forecast annual revenue growth rate of -22.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Abcellera Biologics's revenue in 2026 is $75,128,000.On average, 10 Wall Street analysts forecast ABCL's revenue for 2026 to be $9,444,358,652, with the lowest ABCL revenue forecast at $5,912,235,817, and the highest ABCL revenue forecast at $15,279,288,545. On average, 9 Wall Street analysts forecast ABCL's revenue for 2027 to be $11,508,275,247, with the lowest ABCL revenue forecast at $7,575,980,570, and the highest ABCL revenue forecast at $21,327,340,260.
In 2028, ABCL is forecast to generate $9,914,863,727 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $13,816,236,035.